Currently, there are 105.11M common shares owned by the public and among those 93.19M shares have been available to trade.
The company’s stock has a 5-day price change of 92.06% and 112.98% over the past three months. CORT shares are trading 126.67% year to date (YTD), with the 12-month market performance up to 351.11% higher. It has a 12-month low price of $20.84 and touched a high of $75.00 over the same period. CORT has an average intraday trading volume of 995.56K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 92.30%, 82.13%, and 136.82% respectively.
Institutional ownership of Corcept Therapeutics Inc (NASDAQ: CORT) shares accounts for 80.21% of the company’s 105.11M shares outstanding.
It has a market capitalization of $12.05B and a beta (3y monthly) value of 0.65. The stock’s trailing 12-month PE ratio is 92.63, while the earnings-per-share (ttm) stands at $1.23. The company has a PEG of 1.30 and a Quick Ratio of 3.26 with the debt-to-equity ratio at 0.01. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.10% over the week and 6.36% over the month.
Analysts forecast that Corcept Therapeutics Inc (CORT) will achieve an EPS of 0.15 for the current quarter, 0.41 for the next quarter and 3.59 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 0.08 while analysts give the company a high EPS estimate of 0.08. Comparatively, EPS for the current quarter was 0.25 a year ago. Earnings per share for the fiscal year are expected to increase by 55.28%, and 87.96% over the next financial year. EPS should grow at an annualized rate of 71.00% over the next five years, compared to 9.89% over the past 5-year period.
Looking at the support for the CORT, a number of firms have released research notes about the stock. Truist stated their Buy rating for the stock in a research note on November 06, 2023, with the firm’s price target at $29-$38. SVB Securities coverage for the Corcept Therapeutics Inc (CORT) stock in a research note released on April 11, 2023 offered a Market Perform rating with a price target of $25. Piper Sandler was of a view on April 04, 2023 that the stock is Overweight, while Jefferies gave the stock Hold rating on February 15, 2023, issuing a price target of $35- $22. Truist on their part issued Hold rating on August 01, 2022.
